title: Intraplaque verapamil injection for treatment of Peyronie's disease.
abstract: We report our findings on the effects of intraplaque injection of verapamil for the treatment of Peyronie's disease. We followed 11 men with Peyronie's disease in a nonrandomized constant dose study. During our study, four men received testosterone supplementation; five received vitamin E and/or potassium aminobenzoate (potaba) concurrent with verapamil; two received injections of verapamil only. Plaque size decreased significantly in 7 of 11 patients (55%); softening occurred in 6 (55%); 4 of 8 patients (50%) had decreased curvature. Deformities and symptoms did not recur in any patients who reported improvement. Three of 11 (27%) patients failed treatment and elected to undergo surgical correction. All four (100%) of our study participants with pain had complete resolution after intraplaque verapamil injection compared with Levine et al's 91%. We have demonstrated that intraplaque verapamil injection is a promising treatment for Peyronie's disease in that it may circumvent surgical intervention and may be used with concurrent therapies.
authors.affiliation: Tulane University School of Medicine, New Orleans, La., USA.
authors.forename: A
authors.initials: A
authors.lastname: Lasser
authors.forename: T L
authors.initials: TL
authors.lastname: Vandenberg
authors.forename: M J
authors.initials: MJ
authors.lastname: Vincent
authors.forename: W J
authors.initials: WJ
authors.lastname: Hellstrom
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010411:Penile Induration / Q000628:therapy*; D016896:Treatment Outcome; D014700:Verapamil / Q000008:administration & dosage*
chemical_list: D002121:Calcium Channel Blockers; D014700:Verapamil